Xerox: A Promising Turnaround Story with Significant Upside Potential
Finance

Xerox: A Promising Turnaround Story with Significant Upside Potential

authorBy Robert Kiyosaki
DateJun 24, 2026
Read time2 min

Xerox (XRX) presents a compelling investment case, despite the author's prior hesitation to invest in 2026. The company’s continued efforts toward a significant operational and financial recovery solidify its position as a speculative 'BUY' with a reiterated price target of $6 per share. This positive outlook is underpinned by robust progress in its turnaround strategy and the anticipated benefits from Lexmark synergies, which are expected to drive future growth and profitability.

The company's first-quarter 2026 financial results strongly affirm this optimistic view, showcasing a remarkable 27% increase in revenue. Furthermore, adjusted EBIT tripled, and operating margins significantly improved, confirming the effectiveness of the ongoing recovery initiatives. Xerox is actively managing its financial health through strategic debt reduction, measures to enhance free cash flow, and maintaining a solid liquidity position. Recent opportunistic debt buybacks and a substantial 3.18% dividend yield further highlight the company's commitment to delivering shareholder value and ensuring financial stability.

Despite a notable 50% rally in its stock price, significant additional upside is projected as the full impact of the turnaround and Lexmark synergies has yet to be completely realized. The company’s proactive financial management and strategic initiatives suggest a minimal risk of bankruptcy, making it an attractive prospect for investors seeking growth in a recovering enterprise. As Xerox continues to execute its strategic plan, it is poised to unlock further value and achieve its long-term objectives.

Xerox's journey from a challenging period to a promising future reflects the power of strategic leadership and operational discipline. The company's strong financial performance and prudent management of its balance sheet demonstrate a clear path toward sustainable growth and enhanced shareholder returns. Investing in companies that are undergoing successful transformations, like Xerox, can offer significant rewards as they emerge stronger and more competitive. This resilience and adaptability serve as a testament to the potential for positive change and future prosperity.

More Articles
Finance
Franklin Income SMA's Strong Q1 2026 Performance
The Franklin Income SMA delivered a strong performance in Q1 2026, surpassing its benchmark due to successful fixed income allocations in the energy, healthcare, and materials sectors. Despite attractive absolute yields, credit spreads remain tight. The strategy emphasizes diversification and active management, with opportunistic capital deployment in equities and high-yield bonds to boost income and total returns.
By Fareed ZakariaJun 24, 2026
Finance
John Hancock Diversified Macro Fund: Q1 2026 Performance Overview
The John Hancock Diversified Macro Fund achieved positive returns in Q1 2026, primarily due to successful commodity investments, particularly in energy and metals. The global economic landscape, characterized by evolving geopolitical situations, policy uncertainties, and the growing influence of AI on investment dynamics, led to heightened market volatility and a less predictable environment. Equities and fixed income positions, however, experienced modest losses during this period.
By Nouriel RoubiniJun 24, 2026
Finance
Absci's AI-Driven Antibody Program Gains Eli Lilly Backing Amidst Market Excitement
Absci Corporation's stock surged over 30% following the announcement of a $100 million equity offering, with Eli Lilly as a significant investor. This funding supports Absci's AI-designed antibody, ABS-201, targeting androgenetic alopecia and endometriosis. While Phase 1 safety data is promising, human proof-of-concept is still pending, leading to a 'Hold' rating despite management's optimistic sales projections.
By Lisa JingJun 24, 2026
Finance
MacroGenics: A Strategic Shift to "Hold" Amidst ADC Program Setbacks
MacroGenics, Inc. has been downgraded to a "Hold" rating following recent setbacks in its B7-H3 antibody-drug conjugate (ADC) program. The company's future prospects now largely depend on the successful outcome of MGC026's Phase 1 clinical trial results. MGC026, a uniquely designed B7-H3 ADC, must demonstrate superior efficacy or safety to gain a competitive edge against existing and emerging therapies. Despite these clinical challenges, MacroGenics maintains a robust financial position with $154.2 million in cash as of March 31, 2026, and anticipates sustaining operations until 2028 through various monetization strategies and milestone payments. However, the pipeline faces inherent risks, including the uncertain development of MGC026, the early-stage ADAM9 ADC MGC028, and lorigerlimab, which is encountering efficacy and dosing hurdles in gynecological cancer treatment.
By Suze OrmanJun 24, 2026
Finance
Virtus Newfleet Short Duration High Income Fund Q1 2026 Commentary: Market Dynamics and Fund Performance
This commentary examines the Virtus Newfleet Short Duration High Income Fund's (ASHIX) performance in Q1 2026, noting a 0.00% return against the ICE BofA 1-3Y BB US Cash Pay High Yield Index's 0.19%. It details the high yield market's 0.50% decline and widening credit spreads, influenced by rising yields and geopolitical tensions. The report also touches on portfolio adjustments, sector exposures, and the evolving landscape of high yield issuance.
By Fareed ZakariaJun 24, 2026